Evaluation of Patients With Liver Disease

Learn more about:
Related Clinical Trial
Real World Evidence Study in Subjects With Wilson’s Disease Early Access Program for ALXN1840 in Patients With Wilson Disease Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants Cardiac Involvement in Wilson’s Disease Oral Health and Wilson’s Disease: SOMAWI Gandouling in the Treatment of Wilson’s Disease International Wilson’s Disease Patient Registry (iWilson Registry) Wilson France Register Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease Clinical Features and Outcome of Wilson’s Disease With Generalized Epilepsy in Chinese Patients Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease rTMS in Wilmson Diasease Dysarthria Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 A Phase I/II Study of VTX-801 in Adult Patients With Wilson’s Disease Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease Copper Concentration and Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 Study of Retinal Vascular Parameters in Patients With Wilson’s Disease Evaluation of Patients With Liver Disease ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders The Assessment of Copper Parameters in Wilson Disease Subjects on Standard of Care Treatment Establishment of Human Cellular Disease Models for Wilson Disease Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson’s Disease-related Liver Failure The Individual Therapy for Patients With Wilson’s Disease Study of Zinc for Wilson Disease Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson’s Disease Study of Tetrathiomolybdate in Patients With Wilson Disease Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months WILSTIM – DBS (WILson STIMulation – Deep Brain Stimulation) Efficacy and Safety Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis Inhibitory rTMS in Dystonic Wilson Patients Natural History of Wilson Disease A Registered Cohort Study on Wilson’s Disease sCD163 and sMR in Wilsons Disease – Associations With Disease Severity and Fibrosis Cohort Research on Wilson’s Disease Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson’s Disease Patients Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients

Brief Title

Evaluation of Patients With Liver Disease

Official Title

Evaluation of Patients With Liver Disease

Brief Summary

      The proposed study aims to evaluate, investigate, and follow-up patients suffering from acute
      and chronic liver disease. The study will focus on understanding diseases affecting the
      liver.

      Patients participating in the study will first undergo a routine check-up as an outpatient.
      They will be asked to provide blood and urine samples for laboratory testing and will undergo
      an ultrasound of the liver. Ultrasound examinations use sound waves to determine the size and
      texture of the liver. After the initial visit subjects will be requested to follow-up once a
      year at the outpatient department for a similar check-up.

      Additional tests may be requested throughout the study to provide information for other
      research studies and individual consent will be requested. These tests may include liver
      biopsies, skin biopsies, and / or specialized blood, plasma, and lymphocyte examinations.

      Subjects that qualify for medications presently being studied may be offered the opportunity
      to benefit from experimental therapy.
    

Detailed Description

      Study Description:

      This is a clinical research protocol to allow for collection of samples and data obtained
      during clinical evaluation and long-term follow up of patients who have an acute or chronic
      liver disease. The protocol is designed to create a repository to study the natural history
      and pathogenesis of various liver diseases such as acute and chronic hepatitis B, C, D and E,
      primary biliary cirrhosis, primary sclerosing cholangitis, Wilson's disease, hemochromatosis,
      nonalcoholic steatohepatitis (NASH), noncirrhotic portal hypertension, hepatocellular
      carcinoma, and cryptogenic or poorly defined forms of chronic liver disease. Samples
      collected during the course of clinical care for patients with liver disease include blood,
      saliva, urine, stool, and residual tissue obtained during clinically-indicated liver biopsies
      not otherwise needed for clinical care. Additionally, subjects with liver disease will be
      asked to provide a blood sample for genetic analysis. Healthy volunteers will be recruited
      and asked to provide a blood sample to serve as controls for the genetic analyses. Research
      will be conducted to investigate genetic factors that may contribute to liver diseases

      Objectives: Primary Objective

      To collect data and samples during clinical evaluation, treatment and follow-up of
      participants for future use in studies of liver diseases

      Secondary Objective

      To determine if genetic factors may contribute to the susceptibility, progression, outcome,
      or treatment success of different liver diseases.
    


Study Type

Observational


Primary Outcome

Predisposition and outcomes related to liver disease susceptibility, progression, and treatment response


Condition

Hepatitis D


Study Arms / Comparison Groups

 Healthy individuals
Description:  Healthy individuals who have recovered from liver diseases or who are healthy volunteers

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

8050

Start Date

May 27, 1992



Eligibility Criteria

        -  INCLUSION CRITERIA:

        Affected Subjects

        In order to be eligible to participate in this study, an affected participant must meet all
        of the following criteria:

          1. >=2 years of age.

          2. Meets one of the following:

               1. Suspected or evidence of acute or chronic liver disease on evaluation by a
                  referring licensed independent practitioner (LIP), OR

               2. At risk for acute or chronic liver disease

        Healthy Volunteers

        In order to be eligible to participate in this study, a healthy volunteer must meet all of
        the following criteria:

          1. >= 18 years of age.

          2. In good general health as evidenced by medical history

        EXCLUSION CRITERIA:

        Affected Participants

        An affected participant who meets any of the following criteria will be excluded from
        participation in this study:

        1. History of significant medical illnesses that might interfere with prolonged follow up
        evaluation

        Healthy Volunteers

        A healthy volunteer who meets any of the following criteria will be excluded from
        participation in this study:

          1. Any chronic medical condition, including (but not limited to) heart, kidney, or lung
             diseases

          2. Taking any regular medications or supplements (with the exception of regular
             multivitamins and/or oral contraceptives)

          3. Average alcohol consumption > 1 drink/day in past 6 months, per self-report

          4. History of liver disease (with the exception of neonatal jaundice)

          5. History of severe illness, infection or major surgery in the past year

          6. History of cancer (with the exception of basal cell carcinoma resected > 1 year prior
             to enrollment)

          7. BMI < 18 or BMI >25

          8. Hemoglobin < 11 (women) or hemoglobin < 12 (men)

          9. ALT >35 (men) or ALT >25 (women)

         10. Alkaline Phosphatase >= 150

         11. Bilirubin >2 g/dL

         12. HIV positive, Anti-HCV positive, HBsAg positive or Anti-HBc positive

         13. Pregnancy

         14. Inability to provide informed consent
      

Gender

All

Ages

2 Years - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

T. Jake Liang, M.D., (301) 435-6121, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00001971

Organization ID

910214

Secondary IDs

91-DK-0214

Responsible Party

Sponsor

Study Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)


Study Sponsor

T. Jake Liang, M.D., Principal Investigator, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)


Verification Date

March 24, 2023